Genocea to Host First Quarter 2016 Financial Results Conference Call & Webcast on May 5, 2016

CAMBRIDGE, Mass., April 28, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, May 5, 2016 at 9:00 a.m. ET to discuss financial results for the first quarter of 2016. Genocea management will provide an update on the Company's recent progress and upcoming milestones.

Interested participants and investors may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and refer to conference ID number 91158805. To join the live webcast please visit the investor relations section of the Genocea website at http://ir.genocea.com.

A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.

About Genocea Biosciences Inc.Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (currently seeking partner for Phase 2), and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.

For media:
Liz Bryan
Spectrum Science Communications, Inc.
O: 202-955-6222
[email protected]

For investors:
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-876-8191
[email protected]

You May Also Be Interested In

• SAP Q1 results fall short of Wall Street estimates as transformation kicks off
• SmartFinancial (SMBK) Tops Q1 EPS by 8c
• Semiconductor Tech Firm IceMOS Technology One of Only Ten Exceptional Exporters Honoured in UK Government’s Made in the UK, Sold to the World Awards